$IMTX News

Immatics Announces Extended Data From Phaseb Clinicla Trial Evaluating Anzu-Cel PRAME TCR T-Cell Therapy In Heavily Pretreated Patients With Advanced Melanoma At ASCO Annual Meeting

Analysts Are Updating Their Immatics N.V. (NASDAQ:IMTX) Estimates After Its First-Quarter Results

Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates

Immatics Announces First Quarter 2026 Financial Results and Business Update

Immatics Q1 EPS $(0.50) Misses $(0.42) Estimate, Sales $8.914M Miss $14.590M Estimate

ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth

Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates

All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy

Twist Bioscience (TWST) Reports Q2 Loss, Beats Revenue Estimates

TD Cowen Initiates Coverage On Immatics with Buy Rating

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma

Immatics Announces Its Abstract Regarding Pediatric Participant Treatment With PRAME-Directed Cell Therapy Using Its PRAME T-Cell Receptor Accpected For Poster Presentation At American Association For Cancer Research Annual Meeting 2026

Immatics Phase 3 Progress Sharpens View On Anzu Cel Launch Upside

Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot

Immatics: Q4 Earnings Snapshot

Immatics Announces Full Year 2025 Financial Results and Business Update

Immatics Earnings Report: Q4 Overview

Immatics Q4 EPS $(0.34) Beats $(0.48) Estimate, Sales $23.005M Beat $12.180M Estimate